Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
Anthony Gordon, Paul Mouncey, Farah Al-Beidh, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 16, pp. 1491-1502
Open Access | Times Cited: 1733

Showing 1-25 of 1733 citing articles:

Features, Evaluation and Treatment Coronavirus (COVID-19)
Marco Cascella, Michael Rajnik, Arturo Cuomo, et al.
StatPearls (2020)
Closed Access | Times Cited: 2796
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2021) Vol. 397, Iss. 10285, pp. 1637-1645
Open Access | Times Cited: 1016
A living WHO guideline on drugs for covid-19
Arnav Agarwal, Beverley J. Hunt, Miriam Stegemann, et al.
BMJ (2020), pp. m3379-m3379
Open Access | Times Cited: 962
Drug treatments for covid-19: living systematic review and network meta-analysis
Reed Siemieniuk, Jessica Bartoszko, Dena Zeraatkar, et al.
BMJ (2020), pp. m2980-m2980
Open Access | Times Cited: 796
Neutralizing monoclonal antibodies for treatment of COVID-19
Peter C. Taylor, Andrew C. Adams, Matthew M. Hufford, et al.
Nature reviews. Immunology (2021) Vol. 21, Iss. 6, pp. 382-393
Open Access | Times Cited: 706
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
Peré Domingo, Isabel Mur, Gràcia Mateo, et al.
JAMA (2021) Vol. 326, Iss. 6, pp. 499-499
Open Access | Times Cited: 600
Traumatic brain injury: progress and challenges in prevention, clinical care, and research
Andrew I.R. Maas, David Menon, Geoffrey T. Manley, et al.
The Lancet Neurology (2022) Vol. 21, Iss. 11, pp. 1004-1060
Open Access | Times Cited: 586
Innate immunity: the first line of defense against SARS-CoV-2
Michael Diamond, Thirumala‐Devi Kanneganti
Nature Immunology (2022) Vol. 23, Iss. 2, pp. 165-176
Open Access | Times Cited: 494
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
Evdoxia Kyriazopoulou, Garyphallia Poulakou, Haralampos Milionis, et al.
Nature Medicine (2021) Vol. 27, Iss. 10, pp. 1752-1760
Open Access | Times Cited: 451
Pathophysiology of COVID-19-associated acute kidney injury
Matthieu Legrand, Samira Bell, Lui G. Forni, et al.
Nature Reviews Nephrology (2021) Vol. 17, Iss. 11, pp. 751-764
Open Access | Times Cited: 417
The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries
Martin Hoenigl, Danila Seidel, Agostinho Carvalho, et al.
The Lancet Microbe (2022) Vol. 3, Iss. 7, pp. e543-e552
Open Access | Times Cited: 387
Therapeutic strategies for COVID-19: progress and lessons learned
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 382
Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines
Queenie Fernandes, Varghese Inchakalody, Maysaloun Merhi, et al.
Annals of Medicine (2022) Vol. 54, Iss. 1, pp. 524-540
Open Access | Times Cited: 372
Tackling COVID-19 with neutralizing monoclonal antibodies
Davide Corti, Lisa A. Purcell, Gyorgy Snell, et al.
Cell (2021) Vol. 184, Iss. 12, pp. 3086-3108
Open Access | Times Cited: 369
Severe covid-19 pneumonia: pathogenesis and clinical management
Amy Attaway, Rachel G. Scheraga, Adarsh Bhimraj, et al.
BMJ (2021), pp. n436-n436
Open Access | Times Cited: 366
Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes
Lieuwe D. J. Bos, Lorraine B. Ware
The Lancet (2022) Vol. 400, Iss. 10358, pp. 1145-1156
Closed Access | Times Cited: 352
Target Trial Emulation
Miguel A. Hernán, Wei Wang, David E. Leaf
JAMA (2022) Vol. 328, Iss. 24, pp. 2446-2446
Closed Access | Times Cited: 332
COVID-19-associated fungal infections
Martin Hoenigl, Danila Seidel, Rosanne Sprute, et al.
Nature Microbiology (2022) Vol. 7, Iss. 8, pp. 1127-1140
Open Access | Times Cited: 327
Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial
Michelle Sholzberg, Grace H. Tang, Hassan Rahhal, et al.
BMJ (2021), pp. n2400-n2400
Open Access | Times Cited: 317
Wearable and flexible electrochemical sensors for sweat analysis: a review
Fupeng Gao, Chunxiu Liu, Lichao Zhang, et al.
Microsystems & Nanoengineering (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 307
Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19
Gavin D. Perkins, Chen Ji, Bronwen Connolly, et al.
JAMA (2022) Vol. 327, Iss. 6, pp. 546-546
Open Access | Times Cited: 304
The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19
Christoph Schultheiß, Edith Willscher, Lisa Paschold, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 6, pp. 100663-100663
Open Access | Times Cited: 302
Influenza
Timothy M. Uyeki, David S.C. Hui, Maria Zambon, et al.
The Lancet (2022) Vol. 400, Iss. 10353, pp. 693-706
Open Access | Times Cited: 278
A guide to immunotherapy for COVID-19
Frank L. van de Veerdonk, Evangelos J. Giamarellos‐Bourboulis, Peter Pickkers, et al.
Nature Medicine (2022) Vol. 28, Iss. 1, pp. 39-50
Open Access | Times Cited: 276
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Ly‐Mee Yu, Mona Bafadhel, Jienchi Dorward, et al.
The Lancet (2021) Vol. 398, Iss. 10303, pp. 843-855
Open Access | Times Cited: 263
Page 1 - Next Page

Scroll to top